Clinical trial · Interventional
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-hematologic Malignancy
NCT00754104CI-TRIAL-00004297withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABT-869 | Drug | Linifanib | ALIAS |
| Tarceva | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: ABT-869
- Drug: Tarceva
Primary outcomes (1)
- measure
- Pharmacokinetics
- timeFrame
- Day 7, 15, 21, 35 and Day 1 of every 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subject must have a histologically or cytologically confirmed non-hematologic malignancy. * Subject must have an ECOG Score of 0-2. * Adequate organ function. Exclusion Criteria: * Subject has received targeted VEGF/PDGF therapy (tyrosine kinase inhibitor) therapy. Prior Avastin allowed. * Subject has untreated brain or meningeal metastases. * History of greater than 10% weight loss. * Has clinically relevant hemoptysis. * Subject has proteinuria CTC grade \> 1. * Must not have had radiation therapy or major surgery within 21 days of study day 1. * The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (DBP) \> 100 mmHg or systolic blood pressure (SBP) \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention. * The subject has a documented left ventricular ejection fraction (LVEF) \< 50%.
References
Publications (0)
Data not yet available
No reference posted for this study.